surviv
lung
transplant
limit
larg
part
due
high
incid
chronic
reject
known
chronic
lung
allograft
dysfunct
clad
pulmonari
infect
frequent
complic
lung
transplant
recipi
due
immunosuppress
medic
constant
exposur
lung
allograft
extern
environ
via
airway
infect
recogn
risk
factor
develop
clad
acut
infect
chronic
lung
allograft
colon
microorgan
increas
risk
clad
acut
infect
commun
acquir
respiratori
virus
bacteria
pseudomona
aeruginosa
staphylococcu
aureu
increasingli
recogn
import
risk
factor
clad
colon
fungu
aspergillu
may
also
augment
risk
clad
foster
transit
healthi
lung
clad
infecti
episod
persist
inflammatori
lung
allograft
environ
lung
transplant
first
perform
therapeut
option
patient
endstag
lung
diseas
lung
transplant
surviv
howev
limit
high
incid
chronic
lung
allograft
reject
clad
ultim
result
chronic
respiratori
failur
death
prevent
immedi
reject
transplant
organ
patient
must
receiv
immunosuppress
medic
life
clad
two
form
common
bronchiol
obliteran
syndrom
bo
recent
describ
restrict
allograft
syndrom
clad
defin
decreas
lung
function
notabl
decreas
forc
expiratori
volum
fev
recent
publish
studi
use
bo
measur
clad
outcom
herein
describ
individu
studi
bo
clad
infect
frequent
complic
lung
transplant
major
pulmonari
mani
studi
document
increas
clad
among
specif
pulmonari
infect
articl
part
topic
collect
transplant
oncolog
viru
carv
epidemiolog
studi
switzerland
comprehens
studi
outpati
lung
transplant
recipi
ltr
communityacquir
respiratori
virus
carv
epidemiolog
date
studi
involv
asymptomat
screen
well
routin
followup
emerg
encount
outpati
ltr
commun
virus
found
encount
identifi
routin
emerg
visit
asymptomat
viral
carriag
identifi
screen
visit
overal
ltr
viral
infect
picornavirus
frequent
seen
human
rhinoviru
hrv
certain
condit
may
predispos
ltr
carv
infect
one
studi
elev
blood
level
tacrolimu
identifi
risk
factor
carv
infect
studi
chronic
hrv
ltr
appear
inadequ
host
immun
respons
viru
respons
lack
hrv
clearanc
virusspecif
factor
addit
treatment
acut
cellular
reject
acr
immun
suppress
steroid
may
augment
likelihood
dual
sequenti
viral
infect
moreov
carv
larg
acquir
commun
set
ltr
increas
exposur
time
transplant
increas
sever
studi
found
median
time
carv
ltr
greater
year
particularli
bronchoalveolar
lavag
fluid
balf
sampl
posit
viru
may
one
explan
find
bo
could
risk
carv
bo
typic
develop
year
transplant
thu
appear
immunocompet
host
increas
commun
exposur
perhap
presenc
bo
import
risk
acquisit
carv
earli
studi
impact
carv
upon
lung
allograft
function
tend
case
seri
patient
requir
admiss
hospit
reli
upon
cultur
method
viral
identif
limit
detect
paramyxovirus
influenza
howev
studi
tend
identifi
ltr
sever
diseas
appar
temporari
decreas
fev
frequent
may
persist
often
preced
develop
bo
inde
prospect
swiss
studi
encompass
outpati
inpati
mean
fev
decreas
ml
earlier
studi
found
high
cooccurr
acr
carv
recent
retrospect
studi
well
critic
review
literatur
fail
confirm
associ
greatest
import
impact
carv
upon
develop
clad
one
earliest
report
found
rate
bo
clad
identifi
earlier
studi
among
ltr
surviv
paramyxoviru
adenoviru
infect
anoth
show
within
month
parainfluenza
infect
ltr
develop
bo
median
time
month
infect
center
note
lower
respiratori
tract
carv
infect
risk
factor
develop
bo
month
follow
infect
paramyxovirus
includ
respiratori
syncyti
viru
parainfluenza
viru
appear
often
caus
lower
tract
diseas
perhap
sever
diseas
ltr
respiratori
syncyti
viru
develop
bo
inde
research
suggest
paramyxoviru
survivor
like
progress
bo
overal
symptomat
carv
episod
strongli
associ
bo
within
year
ltr
carv
versu
without
carv
singl
center
studi
ltr
found
carv
lower
respiratori
tract
diseas
carv
increas
hazard
bo
lower
respiratori
tract
carv
greater
impact
statist
signific
recent
anoth
singl
center
studi
similar
size
also
found
carv
lower
tract
diseas
increas
risk
subsequ
clad
risk
pronounc
within
month
carv
episod
recent
review
ltr
center
categor
carv
infect
either
asymptomat
symptomat
without
posit
chest
xray
viral
pneumonia
symptomat
plu
posit
chest
xray
categor
carv
episod
manner
allow
us
answer
question
carv
sever
impact
risk
subsequ
clad
prior
studi
suggest
directli
address
center
viral
pneumonia
significantli
associ
clad
hr
p
asymptomat
symptomat
carv
p
respect
allyn
press
interestingli
found
differ
outcom
whether
cultur
newer
pcrbase
viral
detect
method
use
perhap
parainfluenza
adenovirus
like
caus
clad
readili
identifi
prior
pcr
given
exist
data
appear
probabl
sever
lower
respiratori
tract
viral
infect
associ
increas
risk
clad
patholog
respiratori
viral
infect
studi
underli
mechan
drive
transit
acut
lung
injuri
clad
remain
poorli
understood
therefor
difficult
draw
firm
conclus
mani
commun
respiratori
viral
pathogen
invad
human
epitheli
cell
within
respiratori
tract
known
caus
mark
elev
numer
chemokin
cytokin
regulatori
pathway
addit
sever
ill
may
partial
determin
genet
differ
innat
immun
system
viral
infect
due
influenza
respiratori
syncyti
viru
coronaviru
lead
diffus
alveolar
damag
dad
hemorrhag
dad
begin
acut
exud
phase
wherein
fibrin
deposit
within
airway
prevent
air
exchang
epitheli
cell
damag
may
follow
lead
deposit
hyalin
membran
deposit
clear
organ
phase
dad
develop
prolifer
smooth
muscl
cell
promot
immatur
alveolar
type
ii
cell
follow
deposit
collagen
ultim
fibrosi
yet
clear
pathway
key
determin
progress
dad
fibrosi
patholog
dad
associ
increas
risk
subsequ
clad
put
via
chemokin
axi
shino
et
al
found
balf
level
ligand
time
greater
patient
dad
healthi
control
ligand
modestli
elev
dad
small
studi
ltr
carv
weigt
et
al
assess
impact
balf
concentr
ligand
carv
risk
subsequ
fev
declin
month
postinfect
balf
concentr
time
carv
infect
predict
neg
chang
fev
month
postinfect
attempt
associ
ligand
concentr
presenc
absenc
lower
respiratori
tract
infect
clear
whether
symptomat
lower
tract
diseas
alway
present
suffici
elev
ligand
balf
promot
persist
allograft
dysfunct
viral
infect
lower
respiratori
tract
lead
perturb
numer
cellular
chemokin
pathway
may
virusspecif
unlik
singular
chemokin
axi
sole
respons
associ
carv
infect
bo
studi
employ
transcriptom
approach
necessari
better
understand
patholog
lung
reservoir
cytomegaloviru
cmv
reactiv
within
lung
allograft
transplant
common
though
less
current
valganciclovir
era
sever
studi
found
associ
cmv
pneumon
clad
other
exampl
snyder
et
al
found
treat
cmv
pneumon
first
month
risk
factor
bo
tamm
colleagu
howev
note
treat
cmv
associ
bo
abl
find
differ
surviv
base
upon
donorrecipi
serostatu
cmv
pneumon
associ
inflammatori
lung
allograft
environ
elev
level
predict
bo
effect
cmv
reactiv
infect
develop
clad
present
era
prophylaxi
remain
fulli
defin
epsteinbarr
viru
ebv
herpesviru
contract
remain
perman
resid
within
host
reactiv
time
time
particularli
diminut
cellular
immun
system
requir
viral
control
reactiv
ebv
shed
ebv
within
lung
allograft
blood
occur
approxim
ltr
reactiv
thu
far
definit
associ
subsequ
increas
risk
clad
survey
ltr
found
one
blood
sampl
posit
ebv
pcr
increas
risk
subsequ
bo
role
immunosuppress
reactiv
ebv
examin
relat
studi
group
abl
demonstr
ebv
reactiv
blood
associ
bo
develop
median
followup
time
month
limit
power
detect
bo
neurohr
et
al
look
ebv
reactiv
within
lung
allograft
along
cmv
note
recent
treatment
acr
associ
ebv
balf
posit
interestingli
found
reactiv
ebv
independ
risk
factor
bo
death
recent
interest
role
torqu
teno
midi
viru
anelloviru
lung
transplant
studi
date
signific
correl
anelloviru
allograft
outcom
acr
clad
epidemiolog
fungal
colon
infect
lung
transplant
common
major
due
aspergillu
speci
singl
center
studi
report
colon
rate
aspergillu
multicent
studi
found
cummul
incid
invas
fungal
infect
vast
major
due
aspergillu
speci
studi
shown
associ
aspergillu
colon
increas
risk
subsequ
bo
clad
earliest
studi
effect
fungal
infect
develop
bo
note
bacteri
fungal
infect
well
acut
cellular
reject
acr
associ
develop
bo
ltr
gramposit
bacteria
fungal
infect
larg
aspergillu
spp
held
greatest
risk
subsequ
weigt
et
al
establish
aspergillu
colon
risk
factor
subsequ
bo
singl
center
studi
ltr
cohort
patient
either
develop
colon
invas
infect
due
aspergillu
aspergillu
fumigatu
frequent
encount
speci
multivari
model
contain
acr
aspergillu
colon
covari
found
increas
subsequ
risk
bo
death
due
bo
followup
valid
studi
util
data
patient
duke
univers
ucla
weigt
colleagu
categor
prebo
aspergillu
colon
accord
diamet
conidia
larg
small
speci
small
conidi
speci
includ
fumigatu
nidulan
terreu
flavip
multivari
cox
model
small
conidi
speci
colon
larg
speci
associ
subsequ
bo
death
center
combin
cohort
contrari
studi
peghin
recent
publish
singlecent
experi
lifelong
inhal
ambisom
prophylaxi
invas
fungal
diseas
find
aspergillu
colon
risk
factor
clad
ltr
follow
quit
opposit
found
clad
risk
aspergillu
colon
infect
hr
ci
note
studi
retrospect
review
incid
risk
factor
aspergillu
isol
patient
lifelong
inhal
prophylact
therapi
rate
aspergillu
colon
nearli
half
seen
either
weigt
studi
may
reduc
abil
find
effect
aspergillu
upon
subsequ
clad
also
possibl
lifelong
ambisom
inhal
decreas
risk
clad
develop
aspergillu
colon
accept
least
small
conidi
aspergillu
colon
risk
factor
subsequ
clad
done
reduc
risk
use
lifelong
inhal
ambisom
reduc
risk
colon
subsequ
clad
deriv
aspergillu
one
studi
howev
definit
demonstr
studi
part
know
preambisom
era
aspergillu
colon
risk
factor
clad
mansh
et
al
review
voriconazol
use
ltr
found
voriconazol
use
reduc
colon
ci
well
allcaus
mortal
colon
ci
howev
also
increas
risk
squamou
cell
carcinoma
ci
exposur
voriconazol
associ
risk
either
inhal
ambisom
posaconazol
report
risk
factor
clad
cohort
report
peghin
suggest
longterm
inhal
ambisom
prophylaxi
may
reduc
overal
rate
colon
invas
diseas
howev
second
weigt
studi
found
inhal
amphotericin
compound
prophylaxi
may
favor
colon
small
conidi
speci
hr
ci
case
inhal
amphotericin
may
without
risk
despit
appar
effect
univers
voriconazol
prophylaxi
establish
risk
complic
chronic
voriconazol
increasingli
suggest
limit
role
routin
prophylaxi
studi
requir
confirm
whether
azol
inhal
ambisom
reduc
rate
clad
due
aspergillu
colon
earli
horvath
et
al
note
twothird
pulmonari
infect
ltr
bacteri
subsequ
investig
confirm
bacteri
origin
gramneg
bacteria
make
major
bacteri
infect
pseudomona
aeruginosa
frequent
isol
time
center
like
other
staphylococcu
aureu
frequent
gramposit
bacteria
isol
case
recipi
ps
aeruginosa
aureu
bacteria
ltr
mani
investig
explor
associ
posttranspl
bacteria
transplant
outcom
gottlieb
et
al
examin
effect
gramneg
bacteri
colon
pseudomona
ltr
cystic
fibrosi
note
loss
colon
protect
develop
bo
cox
model
gupta
et
al
valentin
et
al
found
infect
due
gramposit
bacteria
increas
hazard
risk
bo
develop
data
suggest
gramposit
gramneg
mostli
aureu
ps
aeruginosa
respect
infect
colon
like
increas
bo
risk
staphylococcu
moreov
tolllik
receptor
tlr
express
varieti
airway
cell
includ
dendrit
cell
macrophag
aec
respond
broad
rang
pathogen
part
receptor
complex
along
solubl
abund
lung
allograft
solubl
enhanc
bind
lipopolysaccharid
lp
gramneg
bacteria
lipoteicho
acid
gramposit
bacteria
singl
nucleotid
polymorph
within
recipi
associ
decreas
sensit
found
protect
acr
pseudomona
preferenti
caus
cell
activ
prolifer
via
exoenzym
exotoxina
though
exoenzym
may
requir
preprocess
appropri
antigen
present
cell
pseudomona
caus
accumul
lymphocyt
perivascular
space
stimul
cell
produc
associ
allograft
reject
inde
yamamoto
show
murin
orthotop
lung
transplant
model
toler
broken
pseudomona
infect
neutrophil
pseudomonasinfect
uninfect
mice
costimul
cell
via
interact
borthwick
et
al
show
pseudomona
may
role
enhanc
epitheli
mesenchym
transit
possibl
via
interact
tlr
find
suggest
pseudomona
particular
may
enhanc
induc
alloimmun
respons
within
lung
allograft
therebi
provid
potenti
mechan
induct
acr
potenti
clad
within
human
lung
allograft
gramposit
gramneg
organ
accompani
balf
neutrophilia
gramneg
organ
associ
increas
level
elr
chemokin
decreas
lung
function
measur
fev
interact
pseudomona
staphylococcu
chemokineligand
axi
particularli
relev
lung
transplant
elr
chemokin
chemotact
neutrophil
lymphocyt
express
lymphocyt
found
frequent
blood
cystic
fibrosi
patient
noncyst
fibrosi
patient
suggest
chronic
colon
pseudomona
staphylococcu
promot
expans
lymphocyt
pseudomona
infect
colon
within
lung
allograft
may
promot
activ
migrat
lymphocyt
lung
allograft
furthermor
damag
lung
allograft
epithelium
could
caus
pseudomona
staphylococcu
infect
colon
lead
increas
hladr
express
aec
aec
also
releas
solubl
class
hla
stimul
via
metalloproteinasedepend
pathway
pseudomona
staphylococcu
may
therefor
directli
damag
lung
allograft
epithelium
also
recruit
lymphocyt
may
recogn
nonself
protein
potenti
lead
expans
pool
alloreact
lymphocyt
persist
allograft
damag
recent
work
examin
lung
allograft
respons
acr
show
sever
inflammatori
respons
involv
adapt
innat
immun
system
episod
acr
demonstr
elev
innat
pathway
molecul
surfact
well
latter
upregul
lp
gramneg
bacteria
innat
immun
pathway
includ
phagosom
hepatocyt
growth
factor
nitric
oxid
signal
involv
host
respons
bacteri
invas
epitheli
damag
activ
rac
signal
acr
appar
suggest
upstream
pathway
upregul
acr
pathway
suggest
potenti
mechanist
link
acr
fibrot
clad
examin
pseudomona
specif
vo
et
al
evalu
effect
pseudomona
colon
upon
bo
ltr
patient
consid
colon
consecut
pseudomonasposit
sampl
first
three
postop
week
week
month
sampl
patient
bclinic
time
pseudomonasposit
sampl
thu
activ
infect
spearman
univari
analysi
pseudomona
bcolonizationwa
import
risk
factor
bo
multivari
logist
regress
trend
toward
signific
p
small
cohort
year
botha
et
al
also
publish
experi
pseudomona
ltr
colon
also
condit
interest
oppos
infect
colon
split
two
categori
bde
novocolon
meant
pseudomona
isol
prior
transplant
bpersistentcolon
meant
isol
pseudomona
transplant
clear
interven
infect
pseudomona
handl
note
patient
pseudomona
colon
cystic
fibrosi
use
kaplanmei
surviv
analysi
de
novo
colon
transplant
shown
increas
risk
bo
patient
de
novo
colon
risk
bo
increas
seem
cystic
fibrosi
ltr
persist
colon
two
without
cystic
fibrosi
describ
microbiom
australian
postlung
transplant
patient
cystic
fibrosi
willner
et
al
suggest
pseudomona
recolon
allograft
cystic
fibrosi
patient
protect
bo
find
argu
pseudomona
recolon
cystic
fibrosi
patient
transplant
may
harm
respons
botha
studi
vo
et
al
reanalyz
initi
data
split
cohort
persist
de
novo
colon
found
nearli
exact
opposit
colon
persist
colon
wors
cystic
fibrosi
pseudomona
strain
import
mani
chronic
colon
patient
especi
cystic
fibrosi
harbor
mucoid
pseudomona
strain
comparison
mucoid
versu
motil
pseudomona
strain
effect
aec
increas
product
elr
chemokin
although
mucoid
strain
activ
motil
pseudomona
strain
examin
mrna
transcript
aec
cystic
fibrosi
noncyst
fibrosi
patient
stimul
pseudomona
strain
confirm
mutant
nonmut
aec
saw
increas
elr
chemokin
product
howev
mrna
increas
h
mutant
aec
mutant
aec
less
respons
stimul
pseudomona
probabl
increas
basal
chemokinecytokin
product
murin
studi
evalu
effect
bearlyversu
blatemucoid
nonmucoid
pseudomona
strain
cystic
fibrosi
patient
measur
virul
part
elr
chemokin
product
strain
puls
field
gel
electrophoresi
pattern
nonmucoid
strain
demonstr
decreas
virul
time
mucoid
strain
demonstr
increas
stabl
virul
time
significantli
mucoid
strain
abl
inflam
distal
airway
via
migrat
nonmucoid
strain
remain
central
airway
studi
cystic
fibrosi
patient
aaron
et
al
found
acquisit
transmiss
bliverpoolstrain
result
increas
risk
death
lung
transplant
patient
uniqu
nonepidem
strain
pseudomona
drug
resist
may
play
role
strainspecif
effect
interestingli
shteinberg
et
al
found
hazard
develop
bo
increas
quinoloneresist
bacteria
compar
individu
either
quinolonesensit
hr
gramneg
bacteria
hr
transplant
togeth
find
suggest
either
straindepend
differ
de
novo
colon
novel
strain
associ
worsen
lung
function
howev
walter
et
al
mani
other
found
signific
alter
domin
colon
pseudomona
strain
transplant
beg
question
particular
strain
bad
transplant
good
largest
studi
date
pseudomona
lung
transplant
took
decidedli
differ
approach
employ
markov
analysi
determin
statespecif
effect
pseudomona
lung
transplant
markov
analysi
allow
determin
specif
hazard
rate
covari
bstatetransit
first
healthi
posttranspl
state
movement
second
bo
state
measur
risk
covari
yield
move
healthi
condit
without
bo
one
bo
classifi
pseudomona
isol
episod
either
colon
infect
abl
separ
effect
two
condit
importantli
unlik
prior
studi
took
account
inflammatori
environ
allograft
measur
ligand
chemokin
axi
movement
bo
state
significantli
influenc
pseudomona
infect
colon
depend
upon
balf
level
togeth
presenc
pseudomona
elev
level
increas
risk
bo
higher
level
augment
risk
hr
significantli
increas
balf
concentr
independ
associ
subsequ
bo
risk
aspergillu
isol
acr
episod
doserespons
manner
use
similar
approach
investig
effect
staphylococcu
aureu
isol
lung
allograft
function
interestingli
found
aureu
risk
subsequ
bo
present
allograft
level
increas
subsequ
risk
bo
presenc
absenc
aureu
presenc
staphylococcu
augment
effect
hr
per
pgml
versu
hr
inde
neg
effect
staphylococcu
present
concentr
pgml
slightli
differ
model
cohort
overal
pseudomona
colon
infect
significantli
associ
subsequ
bo
hr
acr
thu
studi
staphylococcu
pseudomona
abl
better
understand
relationship
bacteri
infect
colon
subsequ
clad
consid
allograft
inflammatori
state
colon
infect
respiratori
pathogen
result
sever
inflammatori
environ
within
lung
allograft
whether
inflamm
result
infect
appear
like
persist
inflammatori
environ
underli
caus
progress
clad
despit
signific
immunosuppress
postlung
transplant
tremend
inflammatori
environ
found
acr
carv
form
dad
find
pseudomona
staphylococcu
perhap
virus
suggest
underli
allograft
inflammatori
milieu
least
import
determin
graft
fate
infect
pathogenspecif
prophylact
intervent
may
effect
reduc
occurr
posttransplant
impact
clad
cmv
yet
prophylact
strategi
reduc
aspergillu
colon
rate
exist
impact
intervent
subsequ
develop
clad
remain
determin
target
antibiot
therapi
whether
inhal
system
surgic
intervent
sinu
surgeri
may
help
reduc
burden
bacteri
colon
colon
strategi
unlik
great
impact
upon
alreadi
colon
etiolog
carv
divers
preclud
use
virusspecif
intervent
prevent
allograft
damag
therefor
clad
thu
identifi
ltr
greatest
risk
infect
predispos
clad
prioriti
along
appropri
risk
reduct
strategi
via
individu
immunosuppress
studi
requir
illumin
mechan
infecti
organ
promot
gener
clad
allow
us
implement
novel
therapi
direct
sole
pathogen
simultan
deleteri
allograft
respons
pathogen
conflict
interest
dr
gregson
declar
conflict
interest
human
anim
right
inform
consent
articl
contain
studi
human
anim
subject
perform
author
